Discovered in 1958, haloperidol remains a cornerstone of psychiatric care despite its significant risks.
In short: Developed as part of a search for pethidine analogs, haloperidol became the world's most commonly used typical antipsychotic. While it acts rapidly to manage acute psychosis and severe behavioral disorders, its high potency brings a heavy burden of potential side effects, requiring careful clinical management and precise dosing strategies.
Paul Janssen and his team discovered haloperidol in 1958 while investigating the structure-activity relationships of pethidine analogs. Since then, it has become an essential medicine globally, used to treat conditions ranging from schizophrenia and Tourette syndrome to acute delirium and severe nausea. It functions by targeting D2 receptors; clinical research suggests that achieving at least 65% receptor occupancy is necessary for a therapeutic response, while exceeding 78% occupancy significantly increases the likelihood of extrapyramidal side effects.
The drug's potency is a double-edged sword. A 2013 meta-analysis identified haloperidol as the most prone among 15 antipsychotics to cause extrapyramidal symptoms, such as tardive dyskinesia and akathisia, which can be permanent. Furthermore, its use in elderly patients with dementia-related psychosis is associated with a 1.6 to 1.7 times higher risk of death compared to placebo, leading to a boxed warning. Long-term use also necessitates monitoring of metabolic markers like BMI, blood pressure, and lipids due to potential weight gain and other systemic risks.
Modern psychiatric practice has shifted, with newer atypical drugs gaining favor in various situations. However, haloperidol remains indispensable in emergencies, often administered via injection when oral compliance is inconsistent. PET imaging studies have underscored the importance of low-dose strategies, indicating that doses exceeding 5 mg often increase side effects without providing additional efficacy. For those requiring maintenance, international consensus suggests gradual dose reductions to find the lowest effective level, ensuring that the benefits of symptom control are balanced against the drug's complex neurological and physical profile.
Opens the Intellect+ feed with this card first. Swipe up for the next one.
Sources
- Summary by Intellect · source: Haloperidol
To cite this card, link to https://intellectplus.co.uk/app/history-haloperidol.
How we source, check and correct cards: Editorial standards.
General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.
Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?
Related
More in Ancient · More in History · Latest · A–Z · All topics
